


SUMO2 Antibody [clone SPM621] (V2861)

Catalog No.	Formulation	Size
V2861-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2861-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2861SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug
V2861IHC-7ML	Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*	7 ml

[Bulk quote request](#)

Availability	1-3 business days
Species Reactivity	Human
Format	Purified
Host	Mouse
Clonality	Monoclonal (mouse origin)
Isotype	Mouse IgG1, kappa
Clone Name	SPM621
Purity	Protein G affinity chromatography
UniProt	P61956
Localization	Nuclear
Applications	Immunohistochemistry (FFPE) : 1-2ug/ml for 30 min at RT
Limitations	This SUMO2 antibody is available for research use only.



IHC: Formalin-fixed, paraffin-embedded human tonsil stained with SUMO2 antibody (SPM621)

Description

The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO1 and unlike SUMO1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

Application Notes

Optimal dilution of the SUMO2 antibody should be determined by the researcher.

1. Staining of formalin/paraffin tissues requires boiling tissue sections in pH 9 10mM Tris with 1mM EDTA for 10-20 min followed by cooling at RT for 20 min.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Immunogen

Recombinant human protein was used as the immunogen for the SUMO2 antibody.

Storage

Store the SUMO2 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).